Jun08

Solid Biosciences is pleased to announce additional research grant from our Australia-based partner Save Our Sons and an initial research grant from Ireland-based Join Our Boys.

Jun07
  • Jennifer Ziolkowski, CPA, joins as Chief Financial Officer.
  • Carl Morris, Ph.D., promoted to Chief Scientific Officer.
  • Joel Schneider, Ph.D., promoted to Chief Technology Officer, Head of Exploratory R&D.
May11

Solid Biosciences to Initiate Clinical Program for Gene Therapy Candidate in Coming Months

Mar30

Company to Use Proceeds to Advance Programs for Duchenne Muscular Dystrophy.

Mar14

Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017.

Jan30

As we move into 2017, I want to reflect on our journey since founding Solid three years ago and to outline what we hope to accomplish in the coming year.

Jan30

The Duchenne Research Fund (DRF) provided Solid with a research grant of $600,000 to support its LTBP4 program to combat fibrosis and to support novel biomarker work in Duchenne muscular dystrophy (DMD).

Nov10

Grant from Duchenne UK to fund research to better understand the potential benefits of statins in patients with Duchenne muscular dystrophy (DMD).

Pages

More information about Solid?

Please subscribe to receive our latest news